BIT
CBIO

BlackRock Institutional Trust’s Crescent Biopharma CBIO Stock Holding History

BlackRock Institutional Trust’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$457K Buy
749
+136
+22% +$84.9K ﹤0.01% 3477
2016
Q3 		$438K Sell
613
-18
-3% -$13.8K ﹤0.01% 3512
2016
Q2 		$459K Buy
+631
New +$435K ﹤0.01% 3516
2014
Q2 		– Sell
-723
Closed -$1.18M – 3978
2014
Q1 		$1.18M Buy
+723
New +$875K ﹤0.01% 3362

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

BlackRock Institutional Trust's CBIO Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Crescent Biopharma (CBIO) stake by 22% in Q4 2016, buying an estimated $84.9K and bringing the position to 749 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #3477.

BlackRock Institutional Trust first reported a position in CBIO in Q1 2014 and has held it in 4 quarters since. The position peaked at $1.18M in Q1 2014. 50 funds tracked by Wall St. Rank hold CBIO as of Q4 2016.

  • BlackRock Institutional Trust held 749 shares of Crescent Biopharma worth $457K as of Q4 2016.
  • BlackRock Institutional Trust bought 136 Crescent Biopharma shares in Q4 2016, an estimated $84.9K.
  • Crescent Biopharma made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3477 holding.
  • BlackRock Institutional Trust first reported a position in Crescent Biopharma in Q1 2014 and has held it in 4 quarters since.
  • BlackRock Institutional Trust's Crescent Biopharma position peaked at $1.18M in Q1 2014.
  • 50 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.